Patient demographics
Informed consent was obtained from 23 patients. Subsequently, 21 patients received rituximab therapy and CD20 imaging. The remaining 2 patients could not participate in CD20 imaging because of the unavailability of [89Zr]-rituximab and were excluded. Patient characteristics are summarized in Table Baseline characteristics of patient’s clinical and functional data (Never smokerPrevious smokerPack-years (years)66.7% (33.3% (25.5 SD 10.9